Clinical Trials Browser

Phase 2 × INDUSTRY × obinutuzumab × Clear all

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03332017 2026-02-18

ROSEWOOD

Phase 2 Completed

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT04895436 2026-02-09

ReVenG

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04880863 2025-03-03

NT-NAP-102-1

Phase 2 Completed

38 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04189588 2023-10-06

versus

Phase 2 Completed

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

NCT02968563 2022-01-21

Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

35 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02983617 2021-12-21

Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

36 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02320487 2020-02-11

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

102 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02071225 2020-02-07

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Phase 2 Completed

72 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01414855 2018-04-25

A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Phase 2 Completed

100 enrolled 17 charts

Lymphoma, B-Cell

NCT01414205 2017-04-17

A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Phase 2 Completed

80 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01868893 2017-04-17

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2 Completed

20 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00576758 2014-08-19

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

175 enrolled 31 charts

Lymphoma, Non-Hodgkin